Advertisement Pharmaceutical Business review - Page 244 of 5258 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 29, 2026

FDA grants breakthrough status to Biogen’s litifilimab for CLE

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to Biogen’s litifilimab (BIIB059) for cutaneous lupus erythematosus (CLE), a chronic autoimmune skin condition.

Continue
The FDA based its decision on comprehensive data, including findings from the Phase II LILAC study. Credit: Sai Thaw Kyar / Shutterstock.com.
January 29, 2026

Sensorion announces $71.9m reserved offering to expand gene therapy pipeline

The new funding is allocated to drive key milestones for the programme, which targets hearing loss associated with GJB2 mutations. Credit: superbeststock / Shutterstock.com.
January 28, 2026

FDA accepts Otsuka’s centanafadine application for ADHD treatment

Centanafadine showed significant improvements in ADHD symptoms compared with placebo. Credit: Inna Kot / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies
  2. Mirum acquires Bluejay Therapeutics to expand rare liver disease pipeline
  3. FDA to review Eisai’s Leqembi Iqlik sBLA for Alzheimer’s
  4. Johnson & Johnson reports 9.1% increase in sales for Q4 2025
  5. Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis

PRESS RELEASES

SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Pharmaceutical Business Review
Christian Mias to Succeed Andreas Reisse as CEO of SCHOTT Pharma
Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography